Acetylcholinesterase (AChE) is the key enzyme in the breakdown of acetylcholine, and its inhibition is a target for the treatment of Alzheimer’s disease and other neurological disorders including senile dementia, myasthenia gravis, and ataxia [52]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.